Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro
Authors
Keywords
Doxorubicin, AD198, Bladder cancer, Apoptosis
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-11-23
DOI
10.1186/s12885-015-1930-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Biology of Bladder Cancer
- (2015) William Martin-Doyle et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma
- (2013) Shanique K E Edwards et al. BMC CANCER
- PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
- (2013) E Seront et al. BRITISH JOURNAL OF CANCER
- Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells
- (2012) Martin Bezler et al. Molecular Oncology
- Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder
- (2011) Chih-Hao Sun et al. HISTOPATHOLOGY
- Association Between Smoking and Risk of Bladder Cancer Among Men and Women
- (2011) Neal D. Freedman JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phosphatidylinositol 3-Kinase Inhibitor LY294002 Suppresses Proliferation and Sensitizes Doxorubicin Chemotherapy in Bladder Cancer Cells
- (2011) Deyao Wu et al. UROLOGIA INTERNATIONALIS
- Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198)
- (2010) C. Cai et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer
- (2010) Chung-Hsin Chen et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
- (2009) Margaret A. Knowles et al. CANCER AND METASTASIS REVIEWS
- Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo
- (2009) Jin-Ping Lai et al. JOURNAL OF HEPATOLOGY
- Bladder cancer
- (2009) Donald S Kaufman et al. LANCET
- Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: Role for heme oxygenase-1 down-modulation
- (2008) Francesca Bernuzzi et al. CHEMICO-BIOLOGICAL INTERACTIONS
- mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy
- (2008) Paolo Baldo et al. CURRENT CANCER DRUG TARGETS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started